CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Gene Mack Positioned as the Chief Financial Officer at Imcyse

Life Sciences Review Life Sciences Review | Friday, November 26, 2021
Tweet

Gene Mack will contribute his profound understanding and skills of the financial sector to Imcyse as Chief Financial Officer, allowing the company to move forward with its groundbreaking solutions.


Fremont, CA: “I am excited to join Imcyse during this meaningful stage of scientific and corporate growth,” said Gene Mack. “The Company’s novel platform and clinical progress achieved to date uniquely positions Imcyse to deliver on near-term program milestones, and I look forward to working closely with Imcyses exceptionally talented and experienced team to bring revolutionary potential treatment options to patients.” Gene Mack has been named Chief Financial Officer at Imcyse.


Mr. Mack has more than 25 years of expertise in the life sciences industry, specialising in capital markets, business development, and corporate finance. Mr. Mack comes to Imcyse from OncoC4, a privately held biotechnology company that was formed when MSD acquired OncoImmune. He supervised OncoC4's financial establishment in addition to coordinating the successful transaction between the two companies.


 Mr. Mack has served as CFO for a number of biopharmaceutical firms in various stages of development and commercialization, raising approximately $150 million in IPO proceeds and other equity transactions in only the last three years. Mr. Mack provides a proven track record of success in the biotechnology industry, with over $600 million in M&A and licencing transactions to go along with his capital markets skills. Mr. Mack spent over fifteen years as a senior publishing analyst covering biotechnology and life sciences for a number of investment banks, including Gruntal & Co., Lazard, and HSBC, before switching to an operational CFO seven years ago. Gene graduated from Fordham University with a B.S. in Biochemistry and an MBA in Finance.


“We are thrilled to welcome Gene as our new CFO,” said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse. “Gene brings a deep knowledge and expertise of the financial sector, and I am confident that he will be an invaluable addition to our global executive management team as we work to pioneer the next generation of immunotherapeutics in autoimmune diseases.”


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/gene-mack-positioned-as-the-chief-financial-officer-at-imcyse--nwid-644.html